ADCT ADC Therapeutics (ADCT) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001771910
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
69
13F, latest reported quarter
ADC Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for ADC Therapeutics SA in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Apr 1, 2026.
- The trade is 20.8% of the 12,666,731 shares held after it.
- No other insider sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RedCo II Master Fund, L.P. sold about $8.6M of ADCT on Apr 2, 2026, the largest insider sale at the company on our record; 69 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (1 buy, 5 sales), the last on Apr 1, 2026.
- The trade is 24.6% of the 10,265,297 shares held after it.
- No other insider sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RedCo II Master Fund, L.P. sold about $8.3M of ADCT on Apr 2, 2026, the largest insider sale at the company on our record; 69 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Mar 31, 2026.
- The trade is 1.3% of the 12,794,788 shares held after it.
- No other insider sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RedCo II Master Fund, L.P. sold about $617.6K of ADCT on Apr 1, 2026; 69 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on Mar 31, 2026.
- The trade is 1.1% of the 15,301,237 shares held after it.
- No other insider sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RedCo II Master Fund, L.P. sold about $643.2K of ADCT on Apr 1, 2026; 69 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Dec 4, 2024.
- The trade is 1.3% of the 15,470,502 shares held after it.
- No other insider sold within 30 days.
- 69 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RedCo II Master Fund, L.P. sold about $735.9K of ADCT on Mar 31, 2026, the largest insider sale at the company on our record; 69 funds added in the latest 13F quarter.18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
69 funds bought in last quarter
more than 56% of Pharma & Biotech
Revenue
+14.9% year over year
more than 63% of Pharma & Biotech
Margin
-175.3% net margin
below 63% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 52% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ADCT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-62.9%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ADCT: institutional holders (13F)
13F holdings, latest reported quarter
24,652,368 sh
$26.4M
11,526,710 sh
$12.3M
11,390,175 sh
$12.2M
7,824,749 sh
$8.4M
7,020,093 sh
$7.5M
Congress trades in ADCT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ADCT planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ADCT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD U.S. MOMENTUM FACTOR ETF
$1.1M position · as of 2026-05-31
0.1%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$323.8K position · as of 2026-05-31
0.0%
Clearwater Select Equity Fund
$84.9K position · as of 2026-06-30
0.0%
SMALL COMPANY GROWTH PORTFOLIO
$189.5K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$1.8M position · as of 2026-05-31
0.0%
Nuveen Small Cap Blend Index Fund
$160.4K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 69 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ADCT financials
Revenue growth
+14.9%
XBRL, annual
Net margin
-175.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$79.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ADCT
| FY Dec 2025 | $81.4M |
| FY Dec 2024 | $70.8M |
| FY Dec 2023 | $69.6M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $19.2M |
| Mar 2026 | $20.9M |
| Dec 2025 | $23.1M |
| Sep 2025 | $16.4M |
| Jun 2025 | $18.8M |
| Mar 2025 | $23.0M |
| Dec 2024 | $16.9M |
| Sep 2024 | $18.5M |
At each fiscal year end
Single quarter
Net margin, TTM
-121.7%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ADCT
| FY Dec 2025 | -175.3% |
| FY Dec 2024 | -222.8% |
| FY Dec 2023 | -345.2% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -86.1% |
| Mar 2026 | -158.1% |
| Dec 2025 | -27.7% |
| Sep 2025 | -249.4% |
| Jun 2025 | -300.7% |
| Mar 2025 | -167.6% |
| Dec 2024 | -181.4% |
| Sep 2024 | -238.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$102.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ADCT
| FY Dec 2025 | -$141.4M |
| FY Dec 2024 | -$124.7M |
| FY Dec 2023 | -$121.9M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$11.8M |
| Mar 2026 | -$29.7M |
| Dec 2025 | -$31.1M |
| Sep 2025 | -$29.6M |
| Jun 2025 | -$24.1M |
| Mar 2025 | -$56.6M |
| Dec 2024 | -$21.9M |
| Sep 2024 | -$25.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity ADCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-16.55x
TTM operating cash flow over current debt only, 2026-06-30
Cash flow to debt ADCT
| FY Dec 2025 | -47.06x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -16.55x |
| Mar 2026 | -24.71x |
| Dec 2025 | -47.06x |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity ADCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -134.6% |
| FY Dec 2021 | -149.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-32.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ADCT
| FY Dec 2025 | -44.2% |
| FY Dec 2024 | -46.6% |
| FY Dec 2023 | -56.8% |
| FY Dec 2022 | -28.3% |
| FY Dec 2021 | -40.7% |
| Jun 2026 | -32.2% |
| Mar 2026 | -48.6% |
| Dec 2025 | -44.2% |
| Sep 2025 | -52.2% |
| Jun 2025 | -49.0% |
| Mar 2025 | -51.6% |
| Dec 2024 | -46.6% |
| Sep 2024 | -52.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital ADCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-44.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ADCT
| FY Dec 2025 | -49.1% |
| FY Dec 2024 | -49.4% |
| FY Dec 2023 | -47.7% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -44.2% |
| Mar 2026 | -53.9% |
| Dec 2025 | -49.1% |
| Sep 2025 | -53.4% |
| Jun 2025 | -49.2% |
| Mar 2025 | -54.6% |
| Dec 2024 | -49.4% |
| Sep 2024 | -40.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing ADCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$20.1M
market value at close 2026-10-26 on 2026-08-03 shares, plus current debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value ADCT
| FY Dec 2025 | $178.9M |
| FY Dec 2024 | -$58.5M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$76.8M |
| Mar 2026 | $250.0M |
| Dec 2025 | $178.9M |
| Sep 2025 | $215.3M |
| Jun 2025 | $1.2M |
| Mar 2025 | -$55.0M |
| Dec 2024 | -$58.5M |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-53.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield ADCT
| FY Dec 2025 | -32.3% |
| FY Dec 2024 | -64.8% |
| FY Dec 2023 | -91.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -75.2% |
| Mar 2026 | -24.1% |
| Dec 2025 | -32.3% |
| Sep 2025 | -29.4% |
| Jun 2025 | -48.1% |
| Mar 2025 | -97.8% |
| Dec 2024 | -64.8% |
| Sep 2024 | -44.3% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing ADCT
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $81.4M | $70.8M | $69.6M | $209.9M |
| Operating income | -$121.5M | -$130.7M | -$166.0M | -$123.3M |
| Net income | -$142.6M | -$157.8M | -$240.1M | -$157.1M |
| EPS (diluted) | -1.12 | -1.62 | -2.94 | -2.01 |
| Operating cash flow | -$141.2M | -$123.8M | -$118.7M | -$138.3M |
| Cash | $261.3M | $250.9M | $278.6M | $326.4M |
SEC XBRL, fiscal years, as known on 2026-10-27
ADCT Stock Sonar score 5/7 axes
Find similar shapesCompareADCT ranks highest on growth (63rd percentile) and profitability (57th), and lowest on financial health (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
